微循环学杂志
微循環學雜誌
미순배학잡지
CHINESE JOURNAL OF MICROCIRCULATION
2014年
4期
54-59
,共6页
邓文宏%郭闻一%陈辰%王卫星
鄧文宏%郭聞一%陳辰%王衛星
산문굉%곽문일%진신%왕위성
急性胰腺炎%生长抑素%复方丹参注射液%联合用药%Meta分析
急性胰腺炎%生長抑素%複方丹參註射液%聯閤用藥%Meta分析
급성이선염%생장억소%복방단삼주사액%연합용약%Meta분석
Acute pancreatitis%Somatostatin%Compound salvia miltiorrhiza%Combination drug therapy%Meta-an alysis
目的:评价生长抑素联合复方丹参注射液与单用生长抑素治疗急性胰腺炎的疗效。方法:通过 Co-chrane图书馆、Medline数据库、EMbase数据库、CNKI数据库、维普数据库以及万方数据库,检索单用生长抑素(对照组)及联合应用生长抑素和复方丹参注射液(实验组)治疗急性胰腺炎的临床随机对照(RCT)研究文献,按照 Co-chrane指南进行相关研究的筛选与纳入,使用 RevMan 5.1软件进行偏倚风险判断和 Meta 分析,使用 Grade 软件进行证据系统推荐分级,比较对照组和实验组总有效率、并发症发生率及病死率的差异。结果:共纳入 RCT 研究文献10篇,总体偏倚风险一般,Grade系统推荐分级中等。相比于对照组,实验组总有效率较高[RR=1.17,95%CI:(1.08-1.26),P<0.05],并发症发生率较低[RR=0.44,95%CI:(0.30-0.64),P<0.05],病死率较低[RR=0.36,95%CI:(0.17-0.75),P<0.05]。结论:生长抑素联合复方丹参注射液治疗急性胰腺炎比单用生长抑素疗效更好,安全性更高。
目的:評價生長抑素聯閤複方丹參註射液與單用生長抑素治療急性胰腺炎的療效。方法:通過 Co-chrane圖書館、Medline數據庫、EMbase數據庫、CNKI數據庫、維普數據庫以及萬方數據庫,檢索單用生長抑素(對照組)及聯閤應用生長抑素和複方丹參註射液(實驗組)治療急性胰腺炎的臨床隨機對照(RCT)研究文獻,按照 Co-chrane指南進行相關研究的篩選與納入,使用 RevMan 5.1軟件進行偏倚風險判斷和 Meta 分析,使用 Grade 軟件進行證據繫統推薦分級,比較對照組和實驗組總有效率、併髮癥髮生率及病死率的差異。結果:共納入 RCT 研究文獻10篇,總體偏倚風險一般,Grade繫統推薦分級中等。相比于對照組,實驗組總有效率較高[RR=1.17,95%CI:(1.08-1.26),P<0.05],併髮癥髮生率較低[RR=0.44,95%CI:(0.30-0.64),P<0.05],病死率較低[RR=0.36,95%CI:(0.17-0.75),P<0.05]。結論:生長抑素聯閤複方丹參註射液治療急性胰腺炎比單用生長抑素療效更好,安全性更高。
목적:평개생장억소연합복방단삼주사액여단용생장억소치료급성이선염적료효。방법:통과 Co-chrane도서관、Medline수거고、EMbase수거고、CNKI수거고、유보수거고이급만방수거고,검색단용생장억소(대조조)급연합응용생장억소화복방단삼주사액(실험조)치료급성이선염적림상수궤대조(RCT)연구문헌,안조 Co-chrane지남진행상관연구적사선여납입,사용 RevMan 5.1연건진행편의풍험판단화 Meta 분석,사용 Grade 연건진행증거계통추천분급,비교대조조화실험조총유효솔、병발증발생솔급병사솔적차이。결과:공납입 RCT 연구문헌10편,총체편의풍험일반,Grade계통추천분급중등。상비우대조조,실험조총유효솔교고[RR=1.17,95%CI:(1.08-1.26),P<0.05],병발증발생솔교저[RR=0.44,95%CI:(0.30-0.64),P<0.05],병사솔교저[RR=0.36,95%CI:(0.17-0.75),P<0.05]。결론:생장억소연합복방단삼주사액치료급성이선염비단용생장억소료효경호,안전성경고。
Objective:Systematically evaluate the curative effect of somatostatin combined compound salvia miltiorrhiza inj ection and somatostatin alone as a treatment of acute pancreatitis.Method:The Cochrane library,the Medline database,the EMBASE database,the CNKI database,the VIP database and the Wanfang database were searched for the clinical randomized controlled trail investigating somatostatin combined compound salvia miltiorrhiza inj ection for the treatment of acute pancreatitis.Then j udged the studies according to the Cochrane criteria and Grad profiler.A meta-analysis was conducted by the RevMan 5 .1 software.Results:Ten clinical trials were included. The risk of bias of those studies were not up to the mark,and the quality of those trials which was analyzed by Grade were between moderate to very low.Compared with somatostatin alone group,drug application group has a higher total effective rate [RR=1.17,95%CI:(1.08-1.26),P<0.05],a lower incidence of complications [RR=0.44,95%CI:(0.30-0.64),P<0.05],a lower mortality [RR=0.36,95%CI:(0.17-0.75),P<0.05].Conclu-sion:Somatostatin combined compound salvia miltiorrhiza inj ection,as a treatment of acute pancreatitis,has a better curative effect and a more reliable drug safety when compared with the treatment of using somatostatin alone.